(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index futures were down on Tuesday ahead of third-quarter GDP data that could feed into the Federal Reserve's decision on whether to raise interest rates next month. Dow Jones industrial average futures were down 0.74 percent at 17,631, S&P 500 futures were down 0.78 percent at 2,068 and Nasdaq 100 futures were down 0.82 percent at 4,637.25.
** PALO ALTO NETWORKS INC, Monday close $172.02, +2.90 pct premarket
The cyber security company forecast current quarter sales that beat market expectations and reported higher-than-expected quarterly revenue as companies and governments spent more to protect themselves from cyber attacks.
** TIFFANY & CO, Monday close $76.55, -3.92 pct premarket
The upscale jeweler reported a surprise drop in third-quarter sales as strong dollar hurt tourist spending in United States and reduced value of sales from other markets.
** DOLLAR TREE INC, Monday close $69.55, -2.23 pct premarket
The discount retailer reported a 38.4 percent drop in quarterly profit, hurt by expenses related to the integration of its Family Dollar acquisition.
** MICROSEMI CORP, Monday close $36.21, -1.91 pct premarket
** PMC-SIERRA INC, Monday close $11.86, -1.52 pct premarket
** SKYWORKS SOLUTIONS INC, Monday close $77.72, +0.36 pct premarket
Chipmaker Microsemi said it would buy PMC-Sierra in a $2.5 billion deal, ending a months-long bidding war with Skyworks Solutions.
** PINNACLE FOODS INC, Monday close $43.2
** BOULDER BRANDS INC, Monday close $10.07, +8.54 pct premarket
Pinnacle Foods said it would buy natural packaged foods maker Boulder Brands for about $710 million to expand its health and wellness categories.
** NOVARTIS AG, Monday close $86.65, -0.88 pct premarket
The European Commission has approved Novartis’ Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday.
** BRISTOL-MEYERS SQUIBB CO, Monday close $67.99, +0.22 pct premarket
The U.S. Food and Drug Administration has approved Bristol-Myers’ drug, Opdivo, for treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer.
** XEROX CORP, Monday close $10.75, +1.67 pct premarket
Activist investor Carl Icahn disclosed a stake in Xerox and called the printer and copier maker’s shares “undervalued”.
** VALEANT PHARMACEUTICALS INTERNATIONAL INC, Monday close $87.41, +3.25 pct premarket
Activist investor Bill Ackman’s hedge fund has significantly increased its investment in the Canadian drugmaker and signaled it may play a greater role in the beleaguered drugmaker’s strategy, according to a regulatory filing.
** AEROJET ROCKETDYNE HOLDINGS INC, Monday close $16.25, +13.23 pct premarket
Aerojet Rocketdyne on Monday announced contracts from NASA and Boeing Co with a combined value of nearly $1.36 billion, welcome news for the company after several recent financial setbacks.
** SUNEDISON INC, Monday close $3, +8.33 pct premarket
The solar company plans to sell solar power capacity worth about 400 megawatts in India for roughly $350 million, as the U.S.-based firm looks to shed assets to boost balance sheet, said two sources with direct knowledge of the matter.
** J M SMUCKER, Monday close $122.54, -2.07 pct premarket
J M Smucker’s shares down as Vestar Capital Partners exits its remaining stake.
** EMERGENT BIOSOLUTIONS INC, Monday close $37.74
The U.S. Food and Drug Administration approved to expand the use of Emergent’s anthrax vaccine to prevent suspected or confirmed exposure to the bacterium that causes the disease. (Compiled by Rachel Chitra in Bengaluru; Editing by Maju Samuel)